![Prof. Lynne Wagner](https://school.wakehealth.edu/-/media/WakeForest/Global/System/Person-Images/l/Lynne-Wagner.jpg)
De analyse includeerde 552 TAILORx-deelneemsters die bij inclusie en na drie, zes, twaalf, vierentwintig, en zesendertig maanden de 37-item FACT-Cog vragenlijst beantwoordden.De vragenlijst omvatte de 20-item Perceived Cognitive Impairment (PCI)-schaal, het primaire eindpunt van de analyse. De PCI-scores waren in beide armen op alle behandeltijdstippen significant lager dan de baseline-score. In de C+E arm waren de scores na drie en zes maanden significant lager dan in de E-arm, maar vanaf maand twaalf waren de verschillen tussen beide armen niet langer significant.
De onderzoekers concluderen dat adjuvant C+E vergeleken met alleen E geassocieerd was met significant grotere cognitieve stoornis na drie en zes maanden behandeling, maar dat dit verschil na twaalf maanden niet langer significant was.
1.Wagner LI, Gray RJ, Sparano JA et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. J Clin Oncol 2020; epub ahead of print
Summary: A secondary analysis of the TAILORx study found that among women with early breast cancer and a recurrence score 11 to 25, adjuvant chemoendocrine therapy compared with endocrine therapy alone was associated with significantly greater cancer-related cognitive impairment at 3 and 6 months. These differences abated over time and were no longer significant at 12 months and beyond (up to 36 months).